MERGERS AND AQUISITIONS

Over the past several years, the Life Sciences industry has seen a wave of M&A activity.  Many executives view M&A as a means for renewing growth by entering new markets.  However, as history of such M&A activity demonstrates, only a small fraction of such deals will actually create long-term value for shareholders.  In fact, most value creators in Life Sciences have been very selective about their M&A activity and engage in making strategic bets only after a careful and rigorous analysis of the marketplace, evolving customer needs and a deep look at their own core capabilities.

Life Sciences industry presents a particularly challenging landscape for M&A activity. Relative rapid pace of technological innovation, threat of disruption, plethora of emerging companies as well as complex and convoluted IP structures make M&A decision-making process a highly complex one.  Scientia’s Strategic M&A Practice has been designed for the unique aspects of the Life Sciences industry with all the above complexities in mind and is catered to senior executives, board members as well as divisional / product managers to facilitate an efficient and informed decision-making process for strategic M&A activity.